EcoDrugPlus

Monoglyceride Lipase

Ensembl ID : ENSXETG00000002062
Gene Symbol: MGLL
13 Enzyme and pathways 5 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 2

Ensembl ID : ENSXETG00000031971
Gene Symbol: NPR2
5 View Cross-references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 3

Ensembl ID : ENSXETG00000015595
Gene Symbol: NPR3
5 View Cross-references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuronal Acetylcholine Receptor Subunit Alpha-3-Like

Ensembl ID : ENSXETG00000031723
Gene Symbol: LOC101732933
9 Enzyme and pathways 4 View Cross-references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y2

Ensembl ID : ENSXETG00000033846
Gene Symbol: NPY2R
7 Enzyme and pathways 5 View Cross-references
246 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y5

Ensembl ID : ENSXETG00000004893
Gene Symbol: NPY5R
7 Enzyme and pathways 5 View Cross-references
135 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotensin Receptor 1

Ensembl ID : ENSXETG00000047777
Gene Symbol: NTSR1
7 Enzyme and pathways 2 View Cross-references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSXETG00000018040
Gene Symbol: NTRK1
7 Enzyme and pathways 5 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSXETG00000011726
Gene Symbol: NTRK2
8 Enzyme and pathways 5 View Cross-references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSXETG00000033787
Gene Symbol: NTRK3
10 Enzyme and pathways 5 View Cross-references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicastrin

Ensembl ID : ENSXETG00000027247
Gene Symbol: NCSTN
3 Enzyme and pathways 5 View Cross-references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSXETG00000005918
Gene Symbol: NAMPT
5 Enzyme and pathways 5 View Cross-references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).